How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,400 results for

Cholesterol Education Resources

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2001. Comparing the Effects of Oral Contraceptive Pills Versus Metformin

with changes in serum and androgens and markers of insulin sensitivity Changes in lipid particle size and number [ Time Frame: 6 months ] This will be measured by NMR spectroscopy Changes in serum markers of inflammation and free fatty acids. [ Time Frame: 6 months ] Markers of inflammation to be measured are hsCRP, TNF α and IL6 Changes in quality of life parameters in all 3 arms as assessed by PCOSQ [ Time Frame: 6 months ] QOL will be measured by the Polycystic Ovary Syndrome Questionnaire (PCOSQ (...) is planned. Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment Official Title: Comparing the Effects of Oral Contraceptive Pills Versus Metformin in the Medical Management of Overweight/Obese Women With Polycystic Ovary Syndrome Actual Study Start Date : January 1, 2018 Estimated Primary Completion Date : April 30, 2021 Estimated Study Completion Date : April 30, 2022 Resource links provided by the National Library of Medicine related topics: related topics: available

2017 Clinical Trials

2002. Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease

, ischemic stroke and peripheral neuropathy. RVX000222 is a BET inhibitor which modulates the expression of a variety of genes; in a number of Phase 1 and 2 clinical trials RVX000222 significantly affected markers of cardiovascular disease (CVD), such as high-sensitivity C-reactive protein (hs-CRP), alkaline phosphatase, components of the complement and coagulation cascades, and markers of reverse cholesterol transport in patients with CVD. Due to its beneficial effects on several pathways downstream (...) participants Intervention Model: Single Group Assignment Intervention Model Description: Open-label exploratory Masking: None (Open Label) Primary Purpose: Treatment Official Title: An Open-Label Study to Assess the Safety and Effect on Key Biomarkers of Oral RVX000222 in Subjects With Fabry Disease Estimated Study Start Date : September 30, 2019 Estimated Primary Completion Date : September 30, 2020 Estimated Study Completion Date : September 30, 2020 Resource links provided by the National Library

2017 Clinical Trials

2003. Metformin Versus Vildagliptin for Diabetic Hypertensive Patients

with their hypertension and diabetes, groupIII: patients treated with captopril (25mg once daily) for their hypertension in addition to metformin (1000mg bid) groupIV: patients treated with captopril (25mg bid) for hypertension in addition to vildagliptin (50mg bid). At the end of the therapeutic period, then total cholesterol, LDL,serum Creatinine level, blood pressure and vascular endothelial growth factor (VEGF) levels in serum will be measured for different groups to estimate the benefits of one drug over (...) With Hypertension Actual Study Start Date : February 1, 2017 Actual Primary Completion Date : August 1, 2017 Actual Study Completion Date : August 1, 2017 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment No Intervention: Healthy control healthy volunteers not suffering from diabetes or hypertension No Intervention: diabetic hypertensive recently diagnosed patients recently diagnosed patients suffers from diabetes

2017 Clinical Trials

2004. Primary Care

, 2017 Estimated Primary Completion Date : September 30, 2017 Estimated Study Completion Date : October 7, 2017 Resource links provided by the National Library of Medicine related topics: available for: Groups and Cohorts Go to Intervention Details: Device: continuous glucose monitoring (CGM) A CGM device is to be set and take of by the GP. Before the study start all GPs will have a short education on CGM device by the diabetologist who use CGM on a daily base. Study period is seven days and includes (...) , fasting and postprandial glucose, total cholesterol, high density cholesterol, low density cholesterol, triglyceride and serum creatinine) and habits data will be collected. SETTING: Totally 100 of patients will be included. At primary care office each patient wear the device (iPro™2 Medtronic) subcutaneously for up to 7-days and return it to the office for download. Patients do not receive glucose alerts and only see the CGM data after it's been analyzed by the healthcare professional. A CGM device

2017 Clinical Trials

2005. Absorption and Tolerability Studies of an Emulsion Containing the Coconut Oil-derived Glycerol Tridecanoate in Healthy Men

Studies of an Emulsion Containing the Coconut Oil-derived Glycerol Tridecanoate in Healthy Men Estimated Study Start Date : August 28, 2017 Estimated Primary Completion Date : September 24, 2017 Estimated Study Completion Date : March 28, 2018 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Active Glyceryl Tridecanoate emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts Drug: Glyceryl Tridecanoate (...) Glyceryl Tridecanoate (GT) is the triglyceride form of decanoic acid (DA), a C10 fatty acid. GT belongs to the class of medium chain triglycerides (MCT), which has been accepted as a Generally Recognized As Safe food product by FDA. Decanoic acid, also known as capric acid, occurs naturally in coconut oil (8 - 10%) and palm kernel oil (4%). Other Name: GT Placebo Comparator: Placebo Sunflower oil emulsion, single doses (5 g, 10 g, 20 g) to 3 cohorts Other: Placebo Sunflower oil emulsion of equal

2017 Clinical Trials

2006. Prescribing Smart Aging: Integrating Health Systems With Community-Based Lifestyle Interventions

, 2018 Sponsor: University of Kansas Medical Center Information provided by (Responsible Party): University of Kansas Medical Center Study Details Study Description Go to Brief Summary: The purpose of this study is to test the efficacy of delivering an exercise and healthy lifestyle program, Smart Aging, to older adults. Condition or disease Intervention/treatment Phase Aging Health Behavior Behavioral: Smart Aging Program Behavioral: Educational Materials Not Applicable Detailed Description (...) : The Smart Aging Program is designed to be scalable, implementable, and sustainable in the real world. This program joins patients and their clinicians with community-based fitness centers. The Smart Aging Program looks to use already existing resources to deliver an innovative program to increase physical activity in older adults. The program begins at the patient-physician level. The program is conducted in community-based fitness centers, the participant's home (home exercise, monitoring) and also

2017 Clinical Trials

2007. Post-prandial Glycemic Response to Fiber in Healthy Adults

Completion Date : October 31, 2016 Actual Study Completion Date : October 31, 2016 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: High fiber - low fiber Treatment order described in arm title, resistant starch (high fiber muffin top) - conventional flour (low fiber muffin top) Other: resistant starch (high fiber muffin top) Muffin top contained 11 g of fiber per portion Other: control (low (...) after consumption ] IV and capillary Secondary Outcome Measures : Blood insulin response [ Time Frame: 0-4 hours after consumption ] IV Breath hydrogen response [ Time Frame: 0-24 hours after consumption ] Expired air Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may

2017 Clinical Trials

2008. Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

as niacin > 100 mg/day or dietary supplements or prescription omega-3 fatty acids > 1 g/day Type 1 diabetes mellitus Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03071692 Contacts Layout table for location contacts Contact: Senior Clinical Research (...) Purpose: Prevention Official Title: Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) Actual Study Start Date : March 23, 2017 Estimated Primary Completion Date : April 2022 Estimated Study Completion Date : May 2022 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Treatment Group K-877 (pemafibrate) tablet twice daily. Drug: K-877 0.2mg tablet

2017 Clinical Trials

2009. A Smartphone Application to Support Physical Activity in HIV Infected People

et al., 2012). Recently, the investigators performed a pilot study of moderate physical activity that enrolled sedentary HIV infected subjects treated with combination antiretroviral treatment (cART), consisting of brisk walking, with or without strength exercise. Overall, after 12 weeks of training cholesterol profile and soluble and cell inflammatory markers improved significantly. However, because of the considerable individual variability in exercise responses, a program of physical activity (...) activity Outcome Measures Go to Primary Outcome Measures : Physical Fitness [ Time Frame: After 16 weeks of training ] Improvement of 15% of maximal oxygen consumption Secondary Outcome Measures : Anthropometry [ Time Frame: After 16 weeks of training ] BMI in kg/m^2, weight in kilograms, height in meters Anthropometry [ Time Frame: After 16 weeks of training ] Fat Mass in percentage Blood Lipids [ Time Frame: After 16 weeks of training ] Total cholesterol mg/dL^1 Blood Lipids [ Time Frame: After 16

2017 Clinical Trials

2010. Vitamin D Raising and Maintaining Blood Serum 25(OH)D3 Levels

, already taking Vitamin D, any form of steroids, weight-loss drugs, anti-tuberculosis drugs, high blood pressure drugs, high cholesterol drugs, endocrine disease, being treated for any form of cancer. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number (...) ): The Cleveland Clinic Study Details Study Description Go to Brief Summary: Analyze the amount of change in blood serum Vitamin D levels in patients of 3 different dosing groups and how their levels change over a 3 month period of time. Condition or disease Intervention/treatment Phase Vitamin D Deficiency Dietary Supplement: Vitamin D Not Applicable Detailed Description: Vitamin D has shown multiple health benefits specifically in regards to bone healing. To the investigators knowledge there are currently

2017 Clinical Trials

2011. An Open-label, Non-comparative Study to Document the Tolerability to Ramipril in Patients With at Least One High Risk for Developing a Major Cardiovascular Event

23, 2010 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Ramipril Receiving ramipril with the recommended initial dose of 2.5 mg once daily; depending on the tolerability, the dose should be gradually increased. The increase should be implemented by doubling the dose after one to two weeks. Three or four weeks later, the dose should be doubled again up to the usual maintenance dose of 10 mg once daily (...) ] Secondary Outcome Measures : Number of Adverse Events or Serious Adverse Events reported [ Time Frame: 12 weeks ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table

2017 Clinical Trials

2012. Extra Virgin Olive Oil, Red Wine Polyphenols and Fecal Microbiota

Resistance (measured by Homeostasis Model Assessment Insulin Resistance Index (HOMA-IR)) Lipid Profile [ Time Frame: 1 Month ] Changes in lipid profile (LDL, HDL, total cholesterol, triglycerides) Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research (...) Official Title: Extra Virgin Olive Oil and Red Wine Polyphenols in the Modulation of Fecal Microbiota: an Interventional Study Actual Study Start Date : February 2, 2015 Actual Primary Completion Date : May 6, 2015 Actual Study Completion Date : May 6, 2015 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Lean Subjects Part 1: Mediterranean diet with added extra virgin olive oil (80 gr per day) (1 month

2017 Clinical Trials

2013. Cardiovascular Health Promotion Among African-Americans by FAITH!

: Prevention Official Title: Cardiovascular Health Promotion Among African-Americans by FAITH! (Fostering African-American Improvement in Total Health): Engaging the Community Through Mobile Technology-assisted Education Actual Study Start Date : March 2016 Actual Primary Completion Date : June 2017 Actual Study Completion Date : June 2018 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: FAITH! App digital (...) (Minneapolis, St. Paul, MN) churches with predominately African-American congregations. The objective of the study was to partner with churches to implement a multi-component, health education program through the use of core educational sessions delivered through a digital-application accessible on demand via interactive access on computer tablets and the Internet. The overarching goal was to increase the awareness and critical importance of healthy lifestyles for CVD prevention and provide support

2017 Clinical Trials

2014. Evaluation of Statin Mechanism Preventing Cardiovascular Disease by Post-hoc Analysis of Treating to New Targets Study

to 6 years ] The effect of LDL cholesterol lowering amount from baseline LDL-cholesterol on future CV outcome in statin therapy. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general (...) : Completed First Posted : March 8, 2017 Last Update Posted : May 1, 2017 Sponsor: Korea University Guro Hospital Collaborator: Pfizer Information provided by (Responsible Party): Hong Seog Seo, Korea University Guro Hospital Study Details Study Description Go to Brief Summary: Epidemiological studies have shown that serum cholesterol level is correlated with Cardiovascular Disease (CVD) risk, and that Cardiovascular Disease (CVD) risk increases with increasing LDL cholesterol levels. Fortunately, it has

2017 Clinical Trials

2015. Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic Cancer

in cholesterol biosynthesis in patients who had resection with or without Zometa [ Time Frame: up to 5 years ] Change in expression of genes involved in cholesterol biosynthesis in patients who undergo resection will be assessed. Pharmacokinetics parameters of zoledronic acid [ Time Frame: At 0 and 1 hours post zoledronic acid dose, and before radiation treatments on days 2, 3, 4, and 5 ] The concentration of plasma zoledronic acid will be measured.in patients who received zoledronic acid Eligibility (...) Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic Cancer Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results

2017 Clinical Trials

2016. Islet Transplantation Using PKX-001

participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Clinical Study Using Antiaging Glycopeptide (PKX-001) in Islet Transplantation Actual Study Start Date : February 16, 2017 Estimated Primary Completion Date : September 2018 Estimated Study Completion Date : January 2019 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental (...) ] Difference in insulin requirement between treatment group and current standard protocol data Beta-2 score [ Time Frame: Day 0 ] Difference in beta-2 score between treatment group and current standard protocol data Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact

2017 Clinical Trials

2017. The Acute Effect of Egg-Based High Protein Meal on Hypertensive Response to Exercise

Purpose: Diagnostic Official Title: The Acute Effect of Egg-Based High Protein Meal on Hypertensive Response to Exercise Actual Study Start Date : January 1, 2017 Actual Primary Completion Date : June 30, 2017 Actual Study Completion Date : June 30, 2017 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Normal Protein Consumption of normal protein (NP) meal Other: Normal Protein Consumption of a normal (...) : Blood Pressure Changes [ Time Frame: 6hr testing ] Changes from Baseline to Post Systolic Blood Pressure during 30 minute exercise session Secondary Outcome Measures : Vasoactive Molecules [ Time Frame: 6 hrs ] Vasoactive Molecules analysis using plasma Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about

2017 Clinical Trials

2018. Evaluating the Efficacy and Results of Endoscopic Gastroplasty Performed Using Overstitch in Patients With Obesity.

Date : June 1, 2017 Estimated Primary Completion Date : December 31, 2017 Estimated Study Completion Date : December 31, 2017 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Endoscopic gastroplasty Make a gastric tube similar to that obtained in surgical gastroplication however it will be created using intragastric endoscopic sutures. Procedure: Endoscopic gastroplasty Vertical endoscopic gastroplasty (...) Outcome Measures Go to Primary Outcome Measures : Weight loss [ Time Frame: 48 weeks ] Weight in Kg and Body Mass Index (BMI) in kilograms by meters squared Secondary Outcome Measures : Blood count [ Time Frame: 48 weeks ] Measured in cmm Hb1AC [ Time Frame: 48 weeks ] Measured in percentage Cholesterol [ Time Frame: 48 weeks ] Measured in mg/dL Fasting blood glucose [ Time Frame: 48 weeks ] Measured in mg/dL Procedural complications [ Time Frame: At the time of procedure and at 6 months and 1 year

2017 Clinical Trials

2019. "Switch Either Near Suppression Or THOusand"

the threshold at 1000 copies/mL. However, the optimal threshold for defining virological failure and the need to switch ART regimen has not been determined. In fact, people with VL levels of less than 1000 copies/mL, however, not fully suppressed, are at increased risk for drug resistance mutations (DRM) and subsequent virological failure. In resource-limited settings where VL monitoring is not as frequent as in high-income countries, this could have serious implications and patients may continue (...) on a failing regimen for a long period. Our research consortium will conduct a multicenter, parallel-group, open-label, randomized clinical trial in a resource-limited setting to assess whether a threshold of 100 copies/mL compared to the WHO-defined threshold of 1000 copies/mL for switching to second-line ART among unsuppressed HIV-positive patients on first-line ART will lead to better outcomes. Condition or disease Intervention/treatment Phase HIV/AIDS Other: switch Not Applicable Detailed Description

2017 Clinical Trials

2020. Foot Assessment in People With Diabetes: A Quantitative Diagnostic Approach

of identifying the ulceration site will be investigated. Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 153 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Foot Assessment in People With Diabetes: A Quantitative Diagnostic Approach Actual Study Start Date : November 27, 2017 Estimated Primary Completion Date : December 30, 2018 Estimated Study Completion Date : April 1, 2019 Resource links provided by the National (...) ] The biochemistry of the participant's blood is also of great importance in the prediction as well as prevention of foot ulcers. These shall be collected with the participants consent from the central database. The parameters of interest are fasting blood sugar, PPBS, cholesterol, triglycerides, LDL, VLDL and HbA1c . Thermography [ Time Frame: April 2017 to April 2018 every 6 weeks ] A laser thermometer will be used to assess the locations on the foot that have previously experienced ulcers to look

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>